Clinical Data News
-
Caresyntax Announces Highlights of 2023
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
By Caresyntax
-
Rescale and Caresyntax Expand their Collaboration to Provide Scalable Platform for AI-Powered Simulation and Intelligence in Surgery. World Economic Forum Collaboration Enhances Access to Surgical Care and Contributes to Health Equity
Rescale, the leader in cloud high performance computing (HPC) to accelerate innovation and research, and Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, announced a broader collaboration through the World Economic Forum Open Forum for AI in Health and Healthcare Communities. This collaboration marks ...
By Caresyntax
-
Harnessing Wastewater Data to Support Healthcare Ecosystems
Early in the COVID-19 pandemic, wastewater-based epidemiology proved to be a vital tool for hospital systems and healthcare providers in safe operational planning. As wastewater data revealed the impending spike in COVID-19 cases due to the Omicron variant, for example, Boston Children’s Hospital responded by rescheduling nonemergency procedures to limit unnecessary exposure risk. ...
-
Caresyntax Announces Launch of Novel Real World Evidence (RWE) Program and Software Portfolio of Digital Catalysts for Commercial Acceleration of Medtech Partners
Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, today announced the launch of Caresyntax Clinical Data as a Service (CDaaS) for Medtech industry partners. The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical ...
By Caresyntax
-
Caresyntax Announces Strategic Collaboration with AAICO to Expand AI-based Solutions In Healthcare
Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe. With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare ...
By Caresyntax
-
Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation
Caresyntax, the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer by converging AI-powered software, devices, and clinical services, today announced a partnership with ARC (Accelerate, Redesign, Collaborate) Sheba’s Global Innovation platform to establish and replicate the ARC Surgical Innovation Model using the Caresyntax ...
By Caresyntax
-
Vitalograph expands Clinical Trial services portfolio with centralized DLCO, decentralized spirometry, and integrated oscillometry solutions.
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
-
New data from pivotal studies with aflibercept 8 mg
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
By Bayer AG
-
New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
-
The Importance of Optimal Medical Therapy (OMT) and Collaborative Care
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
-
Bayer driving innovation in radiology with new research across the portfolio presented at ECR
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
By Bayer AG
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Clinical Trial Managers Need to Know These Skills for the Future
The Covid-19 epidemic has changed the world in many ways, and many clinical trials have been done to research more about it. According to the World Health Organization (WHO), 12,969 clinical trials were done in America in 2021. Even in pre-pandemic times, clinical trials have always been an ongoing process. Clinical trial managers work on cutting-edge studies and contribute to ...
By Brio Group
-
Are you Using the Right KPIs to Measure Success at your Biotech Company?
A sure sign of a quality organization is the ability to measure its progress and success. “In business, words are words; explanations are explanations, promises are promises, but only performance is reality,” according to Harold S. Geneen, CEO of International Telephone and Telegraph Corp. With the continuous upward trend in productivity of the pharmaceutical ...
By Brio Group
-
The Value of Deep Phenotyping in Genomic Research
Uncovering associations between a disease and relevant genomic variants requires both detailed sequence data and detailed clinical data. Join Genuity Science Principal Scientist Anthony Ryan, PhD as he discusses the importance and value of deep phenotyping when looking for genomic associations to disease. In this video he covers: What is meant by ‘deep’ phenotyping. Why ...
-
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii. “At Castle, ...
-
Inspirata Accelerates Its Growth as a Leading Provider of AI/NLP Technology in Oncology Informatics
Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. This milestone allows the Digital Pathology business to flourish with a partner who has the breadth, depth and ...
-
Unbiased gene fusion analysis required in future cancer diagnostics
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
By Qlucore AB
-
Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you